HANSA BIOPHARMA

Q1 2025 Results Conference Call

April 24, 2025



Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

Q1 2025 Results Conference Call Agenda

24 April 2025



Chairman Remarks	Peter Nicklin Chairman of the Board
Operational Update	Peter Nicklin Chairman of the Board
Pipeline Update	Hitto Kaufmann Chief R&D Officer
Financial Results	Evan Ballantyne Chief Financial Officer
Close and Q&A	Peter Nicklin Chairman of the Board Renée Aguiar-Lucander CEO

Steady growth compared to PY and continued pipeline progress

	Q1 '24	Q1 '25
Sales Revenue	47.4 MSEK	65.7 MSEK
Total Revenue	56.0 MSEK	66.3 MSEK

- ✓ ***39%*** increase in quarterly sales as compared to previous year
- ✓ ***18%*** increase in total revenue as compared to previous year
- ✓ Post Authorization Efficacy and Safety (PAES) study ***fully enrolled***

Ongoing pipeline progress in Q1 2025

Key Trial Progress

ConfIdeS Ph 3 (kidney transplant)
Enrolment complete data read out 2H 2025

PAES Ph 3 (kidney transplant)
Enrolment complete data read out in 2026

GOOD-IDES-02 Ph 3 (anti-GBM)
Enrolment complete data read out in 2025

15-HMedIdeS-09 Ph 2 (GBS)
Ph 2 and indirect treatment comparison data read out

GNT-018-IDES Ph 2 (gene therapy)
Trial initiated in Crigler-Najjar syndrome

SRP-9001-104 Ph 1b (gene therapy)
Trial temporarily halted

NICE-01 Ph 1 (neuroautoimmune)
Ph 1b trial alignment with regulatory agency

HNSA-5487 imlifidase

Publications & Presentations

17-HMedIdes-14 (kidney transplant)
- ✓ Published in *Transplantation Direct*
- ✓ Presentation at an upcoming medical congress

15-HMedIdeS-09 (GBS)
- ✓ Presentation at an upcoming medical congress

Published consensus on use of imlifidase in kidney transplant
- ✓ *Transplant International*: use of imlifidase in the management of highly sensitized kidney transplant patients
- ✓ Spanish guidelines: accepted for publication

PAES study completed enrolment; anticipate increased commercial utilization in key EU markets

ABOUT PAES

- Open label Phase 3 study
- 50 highly sensitized patients with positive crossmatch against an available deceased donor across multiple countries and centers in Europe
- Obligation to the EMA to complete full marketing authorization in the EU

STATUS

- 22 total centers in the trial
- 177 patients consented
- 50 patients treated & transplanted
- Enrolment completed (Jan)

WHAT'S NEXT

- Data readout in 2026
- EMA submission to follow



1. Leeds Teach Hospital NHS Trust-St James University Hospital
2. Leiden University Medical Center
3. Erasmus University Medial Center, Rotterdam
4. CHJU Rouen/Hospital bois Guillaume
5. Necker Hospital, Paris
6. Klinikum rechts der Isar der Technische Universitat Munchen
7. Azienda Ospedaliera di Padova
8. University Medical Centre Ljubjana
9. Azienda Ospedaliero – Universitaria di Parma (Maggiore Hospital)
10. Hospital Universitario Val d'Hebron
11. Hospital Universitario 12 de Octubre, Madrid
12. Hospital Del Mar, Barcelona
13. Hospital Clinic de Barcelona
14. Centre Hospitalier Universitaire (CHU) de Grenoble Aples – Hospital Michallon
15. Medizinische Universtät Wien
16. IKEM Prague
17. Charite – Universitätsmedizin Berlin
18. University Hospital Karolinska
19. University Hospital Uppsala
20. UZ Leuven - Campus Gasthuisberg (Belgium)
21. University Hospital of Leicester (UK)
22. University Medical Center Groningen (Netherlands)

Commercialization of IDEFIRIX in the EU continues to gain momentum

Clinical Readiness

117 clinics are IDEFIRIX ready to treat

40 centers with clinical experience
(4 additional markets in Q1)

66% of clinics in 11 markets have repeat use

Patient Selection & Treatment

200+ local scientific events and global engagements

8 countries issued clinical guidelines

3 international consensus / guidance on desensitization **NEW international consensus on imlifidase published in Transplantation Direct*

Market Access

Reimbursement in 18 markets incl. largest EU markets
**3 additional markets in Jan 2025*

Access in more than 75% of EU transplant market

Q1 2025 Results Conference Call Agenda

24 April 2025



Chairman Remarks	Peter Nicklin Chairman of the Board
Operational Update	Peter Nicklin Chairman of the Board
Pipeline Update	**Hitto Kaufmann** **Chief R&D Officer**
Financial Results	Evan Ballantyne Chief Financial Officer
Close and Q&A	Peter Nicklin Chairman of the Board Renée Aguiar-Lucander CEO

Broad clinical pipeline

	Preclinical	Phase 1	Phase 2	Phase 3	Marketing authorization	Marketed	Partner	Status	Next anticipated milestone
Imlifidase									
EU: Kidney transplantation in highly sensitized patients[1,2]								Commercialization ongoing Post approval Clinical Phase 3 ongoing	EU: Additional agreements around reimbursement / Post authorization study data read out in 2H 2026
U.S. "ConfIdeS": Kidney transplantation in highly sensitized patients[1,2]								Clinical Phase 3 ongoing	Data readout in 2H 2025
GOOD-IDES-02: Anti-GBM antibody disease								Clinical Phase 3 ongoing	Data readout in 2025
16-HMedIdes-12: Active Antibody Mediated Rejection (AMR)								Clinical Phase 2 completed	
15-HMedIdeS-09: Guillain-Barré Syndrome (GBS)								Clinical Phase 2 completed	Publication in peer-reviewed journal Preparation of Phase 3 trial
Investigator-initiated trial in ANCA-associated vasculitis[3]								Clinical Phase 2 ongoing	Complete enrollment (10 patients)
SRP-9001-104: Pre-treatment ahead of gene therapy in Duchenne Muscular Dystrophy (DMD)							SAREPTA THERAPEUTICS	Clinical Phase 1b ongoing	Complete enrollment
Pre-treatment ahead of gene therapy in Limb-Girdle Muscular Dystrophy (LGMD)							SAREPTA THERAPEUTICS	Preclinical research ongoing	Preclinical research
Pre-treatment ahead of gene therapy in Pompe disease							AskBio	Preclinical research ongoing	Preclinical research
GNT-018-IDES: Pre-treatment ahead of gene therapy in Crigler-Najjar syndrome							GENETHON CURE THROUGH INNOVATION	Clinical Phase 2 ongoing	Complete enrollment
HNSA-5487									
NICE-01: HNSA-5487 – Lead candidate from the NiceR program								Clinical Phase 1 completed	Alignment with regulatory authorities on clinical development pathway in neuro-autoimmune diseases

[1] Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)
[2] Lorant et al., American Journal of Transplantation and 03+04 studies (Jordan et al., New England Journal of Medicine)
[3] Investigator-initiated study by Dr. Adrian Schreiber and Dr. Philipp Enghard, at Charité Universitätsmedizin, Berlin, Germany

Advancing the science in Autoimmune, Gene Therapy, and Transplantation

Delivering the Pipeline

8 Ongoing clinical trials in autoimmune, gene therapy and transplantation

Advancing the Science

6 Publications in peer–reviewed journal in Q1 2025

Transplantation DIRECT

Transplant International

American Journal of Transplantation

IMLIFIDASE
IgG cleaving therapy with a unique MOA

AUTOIMMUNE

15-HMedIdeS-09 Ph 2 (GBS)
Indirect Treatment Comparison and
Full data read out COMPLETE

GOOD-IDES-02 Ph 3 (anti-GBM disease)
Enrolment COMPLETE
Data Readout 2H 2025

GENE THERAPY

Sarepta SRP-9001-104 Ph 1b (DMD)
Trial temporarily halted
Data Readout 2025

Genethon GNT-018-IDES Ph 2 (Crigler-Najjar)
Trial INITIATED
Data readout 2025

TRANSPLANTATION

US ConfIdeS Ph 3 (kidney)
Enrolment COMPLETE
Data Readout 2H 2025

16-HMedIdeS-12 Ph 2 (AMR)
Trial COMPLETE
Data published July 2024

Post Authorization Efficacy Ph 3 (kidney)
Enrolment COMPLETE
Trial to complete in 2026

HNSA-5487
next-gen IgG cleaving molecule with redosing potential

NICE-01 FIH Ph 1
Trial and 12mth analysis COMPLETE
Alignment with reg agency on trial design

Long-term follow-up study and extended pooled analysis showed durable graft and patient survival

Study Overview

17-HMedIdeS-14 is a prospective, observational, long-term follow-up study of patients treated with imlifidase prior to kidney transplantation to measure long-term graft survival in patients who have undergone kidney transplantation after imlifidase administration.

Extended pooled analysis with data from 17-HMedIdeS-14 study showed sustained positive outcomes out to five year



- 82% five-year graft survival
- 90% patient survival
- Mean eGFR was 50 mL/min/m2

- Presented at ATC (June 2024)
- Published in *American Journal of Transplantation*[1] (Dec 2024)
- Published in *Transplantation Direct*[2] *(Jan 2025)*
- Published in *American Journal of Transplantation (op-ed)*[3] *(Apr 2025)*

1. Jordan SC, Maldonado AQ, Lonze BE, Sjöholm K, Lagergren A, Montgomery RA, Runström A, Desai NM, Legendre C, Lundgren T, von Zur Mühlen B, Vo AA, Tollemar J, Lefèvre P, Lorant T. Long-term outcomes at 5 years post transplant in imlifidase-desensitized kidney transplant patients. ç. 2024 Dec 4:S1600-6135(24)00742-1. doi: 10.1016/j.ajt.2024.11.029. Epub ahead of print. PMID: 39643005.
2. Jaffe IS, Runström A, Tatapudi VS, Weldon EP, Deterville CL, Dieter RA, Montgomery RA, Lonze BE, Mangiola M. Clinical Outcomes and Donor-specific Antibody Rebound 5 y After Kidney Transplant Enabled by Imlifidase Desensitization. Transplant Direct. 2025 Jan 9;11(2):e1752. doi: 10.1097/TXD.0000000000001752. PMID: 39802198; PMCID: PMC11723687.
3. Jordan, Stanley C.Maldonado, Angela Q.Lonze, Bonnie E.Sjöholm, KristofferLagergren, AnnaMontgomery, Robert A.Runström, AnnaDesai, Niraj M.Legendre, ChristopheLundgren, Torbjörnvon Zur Mühlen, BengtVo, Ashley A.Tollemar, JanLefèvre, PaolaLorant, Tomas et al. American Journal of Transplantation, Volume 25, Issue 4, 878-880

Q1 2025 Results Conference Call Agenda

24 April 2025

Chairman Remarks	Peter Nicklin Chairman of the Board
Operational Update	Peter Nicklin Chairman of the Board
Pipeline Update	Hitto Kaufmann Chief R&D Officer
Financial Results	**Evan Ballantyne** **Chief Financial Officer**
Close and Q&A	Peter Nicklin Chairman of the Board Renée Aguiar-Lucander CEO

Strong Q1 2025 IDEFIRIX sales performance





**From agreements with Sarepta, AskBio & Axis-Shield





*Sales in Q2-2024 and Q3-2024 were offset by a provision totaling 49.6 MSEK.

Continued investments in R&D and commercialization













Summary of cash and headcount









Q1 2025 Results Conference Call Agenda

24 April 2025



Chairman Remarks	Peter Nicklin Chairman of the Board
Operational Update	Peter Nicklin Chairman of the Board
Pipeline Update	Hitto Kaufmann Chief R&D Officer
Financial Results	Evan Ballantyne Chief Financial Officer
Close and Q&A	**Peter Nicklin** **Chairman of the Board** **Renée Aguiar-Lucander** **CEO**

HANSA BIOPHARMA LEADERSHIP

Peter Nicklin

Chairman of the Board

Renée Aguiar-Lucander

CEO

Hitto Kaufmann

Chief R&D Officer

Evan Ballantyne

CFO

Hansa Biopharma contacts and key events

Contacts

Evan Ballantyne

Chief Financial Officer

Email: ir@hansabiopharma.com

Stephanie Kenney

VP, Corporate Affairs

E-mail: media@hansabiopharma.com

Calendar and events

2025

To be Determined	Annual General Meeting 2025
16 JUN	Autoimmune Science Deep Dive – GBS
17 JULY	Half Year Report (January – June)
23 OCT	Interim Report (January – September)


HANSA®
BIOPHARMA